{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:10:21Z","timestamp":1792509021951,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["K23 AR080206"],"award-info":[{"award-number":["K23 AR080206"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23 AR076453"],"award-info":[{"award-number":["K23 AR076453"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R03 AR081309"],"award-info":[{"award-number":["R03 AR081309"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.semarthrit.2023.152335","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T22:36:57Z","timestamp":1701988617000},"page":"152335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer"],"prefix":"10.1016","volume":"64","author":[{"given":"Kaitlin R.","family":"McCarter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senada","family":"Arabelovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily N.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.M.","family":"Vanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth I.","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Gedmintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"MacFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak A.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A.","family":"Shadick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M.","family":"Gravallese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-4618","authenticated-orcid":false,"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.semarthrit.2023.152335_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101805","article-title":"Treatment of rheumatic adverse events of cancer immunotherapy","volume":"36","author":"Reid","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152335_bib0002","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.rdc.2022.02.002","article-title":"Rheumatic complications of immune checkpoint inhibitors","volume":"48","author":"Ghosh","year":"2022","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152335_bib0003","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/M20-3419","article-title":"Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease : a cohort study","volume":"174","author":"van der Kooij","year":"2021","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152335_bib0004","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152335_bib0005","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(23)00064-4","article-title":"Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study","volume":"5","author":"McCarter","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152335_bib0006","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard-2023-223885","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152335_bib0007","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152335_bib0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152335_bib0009","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s41927-022-00297-5","article-title":"Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy","volume":"6","author":"Lusa","year":"2022","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152335_bib0010","article-title":"Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study","author":"Cho","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.semarthrit.2023.152335_bib0011","article-title":"Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study","volume":"35","author":"Beydon","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152335_bib0012","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/L18-0209","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"169","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152335_bib0013","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/ard-2022-222186","article-title":"Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study","volume":"81","author":"Placais","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.semarthrit.2023.152335_bib0014","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152335_bib0015","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152335_bib0016","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RHU.0000000000001314","article-title":"Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis","volume":"27","author":"Efuni","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152335_bib0017","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/imt-2020-0179","article-title":"Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis","volume":"13","author":"Dall'Olio","year":"2021","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152335_bib0018","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.19.01674","article-title":"Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease","volume":"38","author":"Abu-Sbeih","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152335_bib0019","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/1759-7714.14274","article-title":"Immune checkpoint inhibitor-related adverse events in lung cancer: real-world incidence and management practices of 1905 patients in China","volume":"13","author":"Shi","year":"2022","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152335_bib0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12902-022-01004-8","article-title":"Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients","volume":"22","author":"Baek","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"28","key":"10.1016\/j.semarthrit.2023.152335_bib0021","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-Ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152335_bib0022","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152335_bib0023","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"Update of the American college of rheumatology recommended rheumatoid arthritis disease activity measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152335_bib0024","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.semarthrit.2023.152335_bib0025","unstructured":"https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_57.pdf Accessed September 7, 2023."},{"key":"10.1016\/j.semarthrit.2023.152335_bib0026","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152335_bib0027","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1824645","volume":"9","author":"Drakaki","year":"2020","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152335_bib0028","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.21873\/anticanres.14182","article-title":"Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer","volume":"40","author":"Svaton","year":"2020","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152335_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002261","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer","volume":"9","author":"Maslov","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.semarthrit.2023.152335_bib0030","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152335_bib0031","doi-asserted-by":"crossref","DOI":"10.1007\/s10147-023-02406-x","article-title":"Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis","author":"Washino","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152335_bib0032","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152335_bib0033","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamaoncol.2023.0100","article-title":"Steroid dose and duration, immortal time bias, and survival after high-grade immune-related adverse events","volume":"9","author":"Reid","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:19:38Z","timestamp":1778663978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223001774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":33,"alternative-id":["S0049017223001774"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152335","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152335"}}